The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

Exclusion Criteria

• •High risk of bleeding
• •Stroke within 1 month of any history of hemorrhagic or lacunar stroke
• •Severe heart failure with known ejection fraction less than 30% or New York Heart Association (NYHA) class III or IV symptoms
• •Estimated glomerular filtration rate less than 15 mL/min/1.73m2
• •Need for dual-antiplatelet therapy, other non-aspirin antiplatelet therapy, or oral anticoagulant therapy
• •Known non-cardiovascular disease that is associated with poor prognosis (e.g. metastatic cancer) or that increases the risk of an adverse reaction to study interventions
• •History of hypersensitivity or known contraindication to rivaroxaban or aspirin
• •Systemic treatment with strong inhibitors of both CYP 3A4 and p-glycoprotein (e.g. systemic azole antimycotics, such as ketoconazole, and human immunodeficiency virus \[HIV\]-protease inhibitors, such as ritonavir), or strong inducers of CYP 3A4, i.e. rifampicin, rifabutin, phenobarbital, phenytoin, and carbamazepine
• •Any known hepatic disease associated with coagulopathy
• •Subjects who are pregnant, breastfeeding, or are of childbearing potential, and sexually active and not practicing an effective method of birth control (e.g. surgically sterile, prescription oral contraceptives, contraceptive injections, intrauterine device, double- barrier method, contraceptive patch, male partner sterilization)
• •Concomitant participation in another study with investigational drug
• •Upcoming invasive procedure within 3 months
• •Invasive procedure within the prior 1 month
• •Being treated for an active infection
• •Acute or chronic limb-threatening ischemia
• •Known contraindication to any study related procedures